This Market Spotlight report covers the Opioid-Induced Constipation (OIC) market, comprising key marketed and pipeline drugs, clinical trials, probability of success, licensing and asset acquisition deals, and epidemiology data, as well as presenting drug-specific revenue forecasts.

Key Takeaways

• The approved drugs in the opioid-induced constipation (OIC) space predominantly target opioid receptors, with the exception of Amitiza, a type-2 chloride channel activator. All of the marketed drugs are administered via the oral route, with one product also being available in a subcutaneous formulation.
• There are currently no pipeline candidates in development for OIC in the US. The overall likelihood of approval of a Phase I gastroenterology (non inflammatory bowel disease)-other asset is 13.7%, and the average probability a drug advances from Phase III is 59%. Drugs, on average, take 10.3 years from Phase I to approval, compared to 10.1 years in the overall gastroenterology (non inflammatory bowel disease) space.
• The distribution of clinical trials across Phase I–IV indicates that the majority of trials for OIC have been in the late phases of development, with 61% of trials in Phase III–IV, and 39% in Phase I–II.
• Clinical trial activity in the OIC space is dominated by completed trials. Progenics Pharmaceuticals has the highest number of completed clinical trials for OIC, with 13 trials.
• Progenics Pharmaceuticals leads the industry sponsors with the highest overall number of clinical trials for OIC, followed by Pfizer.